NexImmune is a growing biopharmaceutical firm making progress with a novel series of immunotherapies based on our exclusive AIM™ technology. This nanoengineering platform, originally created at Johns Hopkins University, serves as the basis for an inventive approach to immunotherapy where the body's innate immune system is activated to coordinate a precise T cell reaction against a condition. At the core of the AIM technology are synthetic Antigen Presenting Cells (aAPC) that display antigens to T cells, generating a highly specific treatment directed by the patient's immune system.